BioWorld

March 1, 2010

IPO Activity Poised to Pop with Anthera, Aveo and Trius on Deck

It's been nearly a month since Ironwood Pharmaceuticals Inc. tested the biotech initial public offering waters, and now three more biotechs are queued up to price IPOs over the next three weeks. (BioWorld Today) Read More

HCV Combo Approach Keeping Partner Hopes Bright for Idenix

'Clear and Testable Hypothesis' on Pediatric Asthma's Roots

Amicus Adds $18.5M Publicly for Phase III Amigal Program

Collins: NIH Funding Boosts Economy, Spurs Job Growth

Move Over, Cerezyme; Shire's Vpriv Gets Official FDA Nod

Other News To Note

Vital Signs for March 1, 2010

Clinic Roundup

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles

mRNA flu vaccine can activate broad germinal center response

BioWorld

On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...